<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> disorder of the hematopoietic stem cells, frequently characterized by <z:hpo ids='HP_0001903'>anemia</z:hpo> and transfusion dependency </plain></SENT>
<SENT sid="1" pm="."><plain>In low-risk patients, transfusion dependency can be long lasting, leading to <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Iron chelation therapy may be a therapeutic option for these patients, especially since the approval of oral iron <z:chebi fb="0" ids="38161">chelators</z:chebi>, which are easier to use and better accepted by the patients </plain></SENT>
<SENT sid="3" pm="."><plain>The usefulness of iron chelation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients is still under debate, mainly because of the lack of solid prospective clinical trials that should take place in the future </plain></SENT>
<SENT sid="4" pm="."><plain>This review aims to summarize what is currently known about the incidence and clinical consequences of <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients and the state-of the-art of iron chelation therapy in this setting </plain></SENT>
<SENT sid="5" pm="."><plain>We also give an overview of clinical guidelines for chelation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> published to date and some perspectives for the future </plain></SENT>
</text></document>